Table 2.

Clinical features of patients with suspected thrombotic thrombocytopenic purpura following allogeneic bone marrow transplantation.*

Patients with Clinically Suspected TTP (n = 17)Patients in Whom TTP Was Not Suspected (n = 245)P
* Adapted from reference 13. These data describe the experience with allogeneic BMT at the University of Oklahoma, 1989-1998. No patients had clinically suspected TTP following autologous stem cell transplants. Clinically suspected TTP was defined by treatment with plasma exchange. TTP is used as a comprehensive diagnostic term, including syndromes with acute renal failure that may be described as HUS. 
Risk factors for BMT-related complications 
    Severe primary disease 29% 13% 0.08 
    >1 transplant 18% 0.20 
    Unrelated donor 71% 39% 0.02 
    HLA mismatch 35% 16% 0.04 
Occurrence of BMT-related complications 
    Acute GVHD (grade III-IV) 47% 13% <0.01 
    Bacterial sepsis 82% 57% 0.04 
    Viral sepsis 65% 16% <0.01 
    Fungal sepsis 65% 28% <0.01 
Patients with Clinically Suspected TTP (n = 17)Patients in Whom TTP Was Not Suspected (n = 245)P
* Adapted from reference 13. These data describe the experience with allogeneic BMT at the University of Oklahoma, 1989-1998. No patients had clinically suspected TTP following autologous stem cell transplants. Clinically suspected TTP was defined by treatment with plasma exchange. TTP is used as a comprehensive diagnostic term, including syndromes with acute renal failure that may be described as HUS. 
Risk factors for BMT-related complications 
    Severe primary disease 29% 13% 0.08 
    >1 transplant 18% 0.20 
    Unrelated donor 71% 39% 0.02 
    HLA mismatch 35% 16% 0.04 
Occurrence of BMT-related complications 
    Acute GVHD (grade III-IV) 47% 13% <0.01 
    Bacterial sepsis 82% 57% 0.04 
    Viral sepsis 65% 16% <0.01 
    Fungal sepsis 65% 28% <0.01 

or Create an Account

Close Modal
Close Modal